← All trials
NCT04313127
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2020
- Primary completion
- Dec 30, 2020
- Completion date
- Dec 20, 2022
- First posted
- Mar 18, 2020
- Last posted
- Apr 14, 2020
- Enrollment
- 108
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Government of ChinaOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologyCollaborator
- Government of ChinaCollaborator
- People's Liberation Army of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.